Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane (2021) O'Shaughnessy J, Schwartzberg L, Piccart M, Rugo HS, Yardley DA, Cortes J, Untch M, et al. Conference contribution Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/ trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial (2021) Hurvitz SA, Fresco R, Afenjar K, Stroyakovskiy D, Huang CS, Wildiers H, Jung KH, et al. Conference contribution Ribecca - a phase 3b, multi-center, open label study for women with estrogen receptor positive, locally advanced or metastatic breast cancer treated with ribociclib (lee011) in combination with letrozole: Final results (2021) Reinisch M, Nusch A, Decker T, Hartkopf A, Heinrich BJ, Kurbacher CM, Fuchs R, et al. Conference contribution High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated in monarchE (2021) Harbeck N, Johnston S, Fasching P, Martin M, Toi M, Rastogi P, Song C, et al. Conference contribution Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study (2021) Wockel A, Brucker C, Decker T, Falbrede J, Forstbauer H, Gohler T, Hoffmann O, et al. Conference contribution Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells - results from the randomized phase III DETECT III trial (2021) Fehm T, Mueller V, Banys-Paluchowski M, Fasching P, Friedl TWP, Hartkopf A, Huober J, et al. Conference contribution Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program (2021) Muller V, Banys-Paluchowski M, Friedl TWP, Fasching P, Schneeweiss A, Hartkopf A, Wallwiener D, et al. Journal article Global Phase 3 Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy (2021) Rugo H, Chow LWC, Cortes J, Fasching P, He XB, Hsu P, Huang CS, et al. Conference contribution Phase II neoadjuvant study of GDC-9545+palbociclib (palbo) vs anastrozole (A) plus palbo in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC) (2021) Hurvitz SA, Fasching P, Park YH, Quiroga V, Crnjevic TB, Fresco R, Lopez-Valverde V, et al. Conference contribution ABEMACARE: Abemaciclib in combination with endocrine therapy as first line therapy in metastatic breast cancer patients with symptomatic visceral metastases or high tumor burden (2021) Kotzur F, Bidner H, Bronger H, Egert S, Fasching P, Fischer D, Kehl V, et al. Conference contribution